PE20230614A1 - Una terapia combinada con nirogacestat y una terapia dirigida a bcma y usos de estas - Google Patents
Una terapia combinada con nirogacestat y una terapia dirigida a bcma y usos de estasInfo
- Publication number
- PE20230614A1 PE20230614A1 PE2022001961A PE2022001961A PE20230614A1 PE 20230614 A1 PE20230614 A1 PE 20230614A1 PE 2022001961 A PE2022001961 A PE 2022001961A PE 2022001961 A PE2022001961 A PE 2022001961A PE 20230614 A1 PE20230614 A1 PE 20230614A1
- Authority
- PE
- Peru
- Prior art keywords
- bcma
- lymphoma
- therapy
- nirogacestat
- cell
- Prior art date
Links
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 title abstract 5
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 title abstract 5
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 title abstract 4
- VFCRKLWBYMDAED-REWPJTCUSA-N (2s)-2-[[(2s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-n-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide Chemical compound O=C([C@@H](N[C@@H]1CC2=C(F)C=C(F)C=C2CC1)CCC)NC1=CN(C(C)(C)CNCC(C)(C)C)C=N1 VFCRKLWBYMDAED-REWPJTCUSA-N 0.000 title abstract 2
- 229950001637 nirogacestat Drugs 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 abstract 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 abstract 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 abstract 2
- 201000003444 follicular lymphoma Diseases 0.000 abstract 2
- 208000025113 myeloid leukemia Diseases 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 208000011691 Burkitt lymphomas Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 229940127121 immunoconjugate Drugs 0.000 abstract 1
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- -1 tetrahydronaphthalen-2-yl Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062989372P | 2020-03-13 | 2020-03-13 | |
| PCT/US2021/022177 WO2021183934A1 (en) | 2020-03-13 | 2021-03-12 | A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230614A1 true PE20230614A1 (es) | 2023-04-14 |
Family
ID=75396879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001961A PE20230614A1 (es) | 2020-03-13 | 2021-03-12 | Una terapia combinada con nirogacestat y una terapia dirigida a bcma y usos de estas |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230121547A1 (enExample) |
| EP (1) | EP4132515B1 (enExample) |
| JP (2) | JP7781764B2 (enExample) |
| KR (1) | KR20230009873A (enExample) |
| CN (2) | CN115916188A (enExample) |
| AR (1) | AR121566A1 (enExample) |
| AU (1) | AU2021236340A1 (enExample) |
| BR (1) | BR112022018251A2 (enExample) |
| CA (1) | CA3171267A1 (enExample) |
| CL (1) | CL2022002479A1 (enExample) |
| CO (1) | CO2022014388A2 (enExample) |
| IL (1) | IL296075A (enExample) |
| MX (1) | MX2022011258A (enExample) |
| PE (1) | PE20230614A1 (enExample) |
| TW (1) | TW202200132A (enExample) |
| WO (1) | WO2021183934A1 (enExample) |
| ZA (1) | ZA202209989B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024002590A (es) | 2021-09-01 | 2024-03-22 | Springworks Therapeutics Inc | Sintesis de nirogacestat. |
| WO2023064872A1 (en) * | 2021-10-14 | 2023-04-20 | Precision Biosciences, Inc. | Combinations of anti-bcma car t cells and gamma secretase inhibitors |
| CN118338900A (zh) * | 2021-11-05 | 2024-07-12 | 斯普林渥克斯治疗有限公司 | 含尼罗加司他的组合物和治疗 |
| MX2024005453A (es) * | 2021-11-05 | 2024-07-22 | Springworks Therapeutics Inc | Composiciones y tratamientos con nirogacestat. |
| EP4436958A1 (en) * | 2021-11-23 | 2024-10-02 | Teva Pharmaceuticals International GmbH | Solid state forms of nirogacestat salts |
| US11951096B2 (en) | 2022-05-20 | 2024-04-09 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| US12138246B2 (en) | 2022-05-20 | 2024-11-12 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| IL316750A (en) | 2022-05-20 | 2025-01-01 | Springworks Therapeutics Inc | Treatments with Nirogesstat |
| US12667555B2 (en) | 2022-05-20 | 2026-06-30 | Springworks Therapeutics, Inc. | Treatment of ovarian cancer with nirogacestat |
| US12036207B2 (en) | 2022-05-20 | 2024-07-16 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| JP2026508907A (ja) * | 2023-03-09 | 2026-03-13 | ▲蘇▼州科睿思制▲葯▼有限公司 | ニロガセスタット二臭化水素酸塩の結晶形、及びその調製方法並びに用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015120065A1 (en) * | 2014-02-05 | 2015-08-13 | The Trustees Of Columbia University In The City Of New York | Gamma-secretase inhibition reduce apoc3 levels and plasma triglycerides |
| EP3324965A4 (en) * | 2015-07-24 | 2019-07-03 | Oncotracker, Inc. | Gamma secretase modulators for the treatment of immune system dysfunction |
| IL268349B2 (en) * | 2017-02-17 | 2024-08-01 | Hutchinson Fred Cancer Res | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| EP3615068A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| EP3615055A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| CN110622566B (zh) | 2017-05-05 | 2021-04-20 | 华为技术有限公司 | 一种辅助数据传输方法、设备及系统 |
| AU2018359907A1 (en) * | 2017-11-06 | 2020-05-07 | Fred Hutchinson Cancer Center | Combination of a cell therapy and a gamma secretase inhibitor |
| US11970542B2 (en) * | 2017-11-08 | 2024-04-30 | Fred Hutchinson Cancer Center | Bispecific antibodies specific for treating hematological malignancies |
| WO2019143818A1 (en) * | 2018-01-17 | 2019-07-25 | Mingsight Pharmaceuticals, Inc. | Combination therapy for the treatment of cancer |
| BR112020023975A2 (pt) * | 2018-05-24 | 2021-02-23 | Ayala Pharmaceuticals Inc. | composições que compreendem os compostos de bisfluoroalquil-1,4-benzodiazepinona e imunoterapêuticos e métodos de uso das mesmas |
| PE20210320A1 (es) * | 2018-06-01 | 2021-02-16 | Novartis Ag | Moleculas de union contra bcma y usos de las mismas |
| MX2021012407A (es) * | 2019-04-10 | 2021-11-12 | Glaxosmithkline Ip Dev Ltd | Terapia de combinacion con un anticuerpo anti bcma y un inhibidor de gamma secretasa. |
| KR102772889B1 (ko) | 2019-08-09 | 2025-02-26 | 화이자 인코포레이티드 | (s)-2-(((s)-6,8-디플루오로-1,2,3,4-테트라하이드로나프탈렌-2-일)아미노)-n-(1-(2-메틸-1-(네오펜틸아미노)프로판-2-일)-1h-이미다졸-4-일)펜탄아미드의 고체 상태 형태 및 이의 용도 |
-
2021
- 2021-03-12 CN CN202180034598.4A patent/CN115916188A/zh active Pending
- 2021-03-12 JP JP2022554833A patent/JP7781764B2/ja active Active
- 2021-03-12 AU AU2021236340A patent/AU2021236340A1/en active Pending
- 2021-03-12 WO PCT/US2021/022177 patent/WO2021183934A1/en not_active Ceased
- 2021-03-12 AR ARP210100641A patent/AR121566A1/es unknown
- 2021-03-12 MX MX2022011258A patent/MX2022011258A/es unknown
- 2021-03-12 CN CN202610227254.XA patent/CN122272572A/zh active Pending
- 2021-03-12 PE PE2022001961A patent/PE20230614A1/es unknown
- 2021-03-12 TW TW110108930A patent/TW202200132A/zh unknown
- 2021-03-12 IL IL296075A patent/IL296075A/en unknown
- 2021-03-12 EP EP21716907.7A patent/EP4132515B1/en active Active
- 2021-03-12 BR BR112022018251A patent/BR112022018251A2/pt unknown
- 2021-03-12 KR KR1020227034017A patent/KR20230009873A/ko active Pending
- 2021-03-12 US US17/906,089 patent/US20230121547A1/en active Pending
- 2021-03-12 CA CA3171267A patent/CA3171267A1/en active Pending
-
2022
- 2022-09-07 ZA ZA2022/09989A patent/ZA202209989B/en unknown
- 2022-09-12 CL CL2022002479A patent/CL2022002479A1/es unknown
- 2022-10-10 CO CONC2022/0014388A patent/CO2022014388A2/es unknown
-
2025
- 2025-08-25 JP JP2025139609A patent/JP2025168430A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115916188A (zh) | 2023-04-04 |
| JP2023517243A (ja) | 2023-04-24 |
| KR20230009873A (ko) | 2023-01-17 |
| MX2022011258A (es) | 2023-01-11 |
| CO2022014388A2 (es) | 2023-02-16 |
| CA3171267A1 (en) | 2021-09-16 |
| WO2021183934A1 (en) | 2021-09-16 |
| BR112022018251A2 (pt) | 2022-11-08 |
| ZA202209989B (en) | 2025-12-17 |
| TW202200132A (zh) | 2022-01-01 |
| JP7781764B2 (ja) | 2025-12-08 |
| EP4132515B1 (en) | 2026-08-05 |
| JP2025168430A (ja) | 2025-11-07 |
| IL296075A (en) | 2022-11-01 |
| CN122272572A (zh) | 2026-06-26 |
| US20230121547A1 (en) | 2023-04-20 |
| AU2021236340A1 (en) | 2022-09-29 |
| CL2022002479A1 (es) | 2023-08-18 |
| AR121566A1 (es) | 2022-06-15 |
| EP4132515A1 (en) | 2023-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2004001291A (es) | Alquinos como inhibidores de metaloproteinasa de matriz ref. pc20536 | |
| PE20110549A1 (es) | EL COMPUESTO 3-(4-CLORO-2-FLUOROBENCIL)-2-METIL-N-(5-METIL-1H-PIRAZOL-3-IL)-8-(MORFOLINOMETIL)IMIDAZO[1,2-b]PIRIDAZIN-6-AMINA, SUS SALES Y LA COMPOSICION QUE LO COMPRENDE | |
| ES2524966T3 (es) | Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer | |
| CY1118846T1 (el) | Τριαζολοπυριδαζινες ως ρυθμιστες της κινασης τυροσινης | |
| BRPI0412347A (pt) | 2-aminofenil-4-fenilpiridinas como inibidores de quinase | |
| ECSP109965A (es) | Imidazoles fusionados para el tratamiento del cancer | |
| TW200714589A (en) | Phenylacetamides suitable as protein kinase inhibitors | |
| JP2008535902A5 (enExample) | ||
| PL1631295T3 (pl) | Zastosowanie skondensowanych związków heterocyklicznych jako inhibitorów SCCE do leczenia chorób skóry | |
| GT200500103A (es) | 4-fenilamino-quinazolin-6-il-amidas | |
| EA201190002A1 (ru) | Лечение антителами к интегрину альфа-2 | |
| GT201100181A (es) | "inhibidores de proteina cinasa" | |
| PE20070766A1 (es) | Polimorfos de la sal benzoato de 2-((6-(3r)-3-amino-1-piperidinil)-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil)metil)benzonitrilo y metodos para usarlos | |
| MX2024009943A (es) | Inhibidores de arn helicasa dhx9 y usos de los mismos | |
| NZ620000A (en) | Prodrug forms of kinase inhibitors and their use in cancer therapy | |
| ECSP088828A (es) | 4-anilinoquinolina-3-carboxamidas como inhibidores de la quinasa csf-1r | |
| EA201070013A1 (ru) | СОЛИ ИНГИБИТОРА ЯНУС-КИНАЗЫ (R)-3-(4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1H-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА | |
| GT200300005A (es) | 2-(piridin-2-ilamino)-pirido[2,3-d] pirimidin-7-onas | |
| ECSP10010361A (es) | Derivados de piridazinona | |
| AR057056A1 (es) | Proceso para la sintesis de imidazol bencilaminas | |
| BR112022009336A2 (pt) | Combinação de inibidor de btk e inibidor de mdm2 para tratamento de câncer | |
| CY1114140T1 (el) | Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο | |
| ECSP099722A (es) | Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncer | |
| BRPI0606463A2 (pt) | derivados triazol substituìdos com antagonistas de oxitocina | |
| DK1888063T3 (da) | Antimykotiske midler |